Gianfranco Scaperrotta
Overview
Explore the profile of Gianfranco Scaperrotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Irmici G, Cozzi A, Depretto C, Della Pepa G, Ancona E, Bonanomi A, et al.
Eur J Radiol
. 2025 Mar;
185:112012.
PMID: 40031378
Purpose: To assess the impact of an artificial intelligence decision support system (Koios DS) on the diagnostic performance of radiologists with different experience in breast ultrasound and to evaluate its...
2.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, et al.
Cell Metab
. 2024 Dec;
37(2):330-344.e7.
PMID: 39694040
In preclinical experiments, cyclic fasting-mimicking diets (FMDs) showed broad anticancer effects in combination with chemotherapy. Among different tumor types, triple-negative breast cancer (TNBC) is exquisitely sensitive to FMD. However, the...
3.
Ciniselli C, Verderio P, Baili P, Sant M, Pizzamiglio S, Duroni V, et al.
Clin Breast Cancer
. 2024 Aug;
25(1):e79-e85.e1.
PMID: 39209598
Background: Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer, with 5-10% of cases progressing into invasive disease. Herein, we investigated the association between HER2-low...
4.
Irmici G, Cozzi A, Della Pepa G, De Berardinis C, DAscoli E, Cellina M, et al.
Radiol Med
. 2024 Aug;
129(10):1463-1467.
PMID: 39138732
Applications of large language models (LLMs) in the healthcare field have shown promising results in processing and summarizing multidisciplinary information. This study evaluated the ability of three publicly available LLMs...
5.
Vidali S, Irmici G, Depretto C, Bellini C, Pugliese F, Incardona L, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123423
Neoadjuvant chemotherapy (NAT) plays a crucial role in breast cancer (BC) treatment, both in advanced BC and in early-stage BC, with different rates of pathological complete response (pCR) among the...
6.
Irmici G, Ce M, Della Pepa G, DAscoli E, De Berardinis C, Giambersio E, et al.
Crit Rev Oncog
. 2024 Mar;
29(2):15-28.
PMID: 38505878
Breast ultrasound has emerged as a valuable imaging modality in the detection and characterization of breast lesions, particularly in women with dense breast tissue or contraindications for mammography. Within this...
7.
Ligorio F, Lobefaro R, Fuca G, Provenzano L, Zanenga L, Nasca V, et al.
Int J Cancer
. 2023 Aug;
154(1):114-123.
PMID: 37615485
Severe calorie restriction, in the form of cyclic fasting or fasting-mimicking diets (FMDs), boosts the antitumor activity of cytotoxic chemotherapy in mouse models of triple-negative breast cancer (TNBC). This effect...
8.
Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fuca G, Rametta A, et al.
Clin Breast Cancer
. 2023 Jan;
23(3):e151-e162.
PMID: 36599769
Background: Platinum-based chemotherapy is widely used in patients with advanced triple-negative breast cancer (TNBC). However, the most effective platinum-based combination in the first-line treatment setting remains unclear. Materials And Methods:...
9.
Di Cosimo S, La Rocca E, Ljevar S, De Santis M, Bini M, Cappelletti V, et al.
Front Mol Biosci
. 2022 Oct;
9:996434.
PMID: 36225259
Previous data, mostly from clinical trials, reported that HER2-low status is associated with low pathological complete response (pCR), and favourable prognosis. Since these findings suggest the existence of an additional...
10.
Giussani M, Ciniselli C, De Cecco L, Lecchi M, Dugo M, Gargiuli C, et al.
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439180
In population-based screens, tissue biopsy remains the standard practice for women with imaging that suggests breast cancer. We examined circulating microRNAs as minimally invasive diagnostic biomarkers to discriminate malignant from...